Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease
Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study
Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation
Phase III Regorafenib Trial Meets PFS Primary Endpoint
Radium-233 Dichloride Increased Overall Survival in Phase III Trial
Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone
Nexavar Phase III Trial Fails To Meet Primary Endpoint
Alimta/Cisplatin Chemotherapy Increased Overall Survival
New Carfilzomib Combination Produces Near Remissions
Trial Data: No Benefit In Adding Perifosine to Capecitabine
Blinatumomab Demonstrates High Response Rate in ALL
MET Inhibitor Improved Time To Progression by 56 Percent
NCI-Approved CTEP Trials For The Month of June
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored
